drugset / Trial / NCT04229706

A Study of Xiangjurupining Capsule in the Treatment of Hyperplasia of Breast (Liver Stagnation and Phlegm Coagulation)

NCT04229706 ↗

Phase 2 Completed 180 enrolled Tasly Pharmaceutical Group Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is to evaluate the efficacy and safety of two doses of xiangjurupining capsule in Hyperplastic disease of breast patients .

Timeline

Start
2019-12-31
Primary completion
2022-01-12
Completion
2022-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Xiang Ju Ru Pi Ning Unknown 4 unknown —
Subject Xiang Ju Ru Pi Ning Unknown 8 unknown —

Indications